Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2305014 | 0.84 | HSD17B3 (0.60) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14918369 | 0.83 | CA1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21456549 | 0.83 | SMN1; SMN2 (0.52) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL333688 | 0.83 | CA1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17295082 | 0.83 | CA1 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1201267 | 0.83 | NPC1 (0.62) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL8085697 | 0.82 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3987484 | 0.82 | NPC1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL452462 | 0.82 | PLOD2 (0.56) | NPC1RAB9APTPN1MEN1KMT2A | |
| SCHEMBL11827259 | 0.82 | GSK3B (0.55) | NPC1RAB9AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | BIOENERGENIX LLC (US) | 2021-03-23 | — | — | US | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| EP-2595952-B1 | AGONISTS OF GPR40 | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2020-11-18 | — | — | EP | disclosed |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-10 | — | — | US | disclosed |
| CN-107266416-B | Aryldihydropyridinones and piperidones as MGAT2 inhibitors | 百时美施贵宝公司 | 2020-07-10 | — | — | CN | disclosed |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190314346-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | ARENA PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | disclosed |
| CN-1751038-A | Substituted aryl and heteroaryl derivatives as modulators of glucose metabolism and the prophylaxis and treatment of disorders thereof | ARENA PHARM INC (US) | 2006-03-22 | — | — | CN | disclosed |
| EP-1606282-A2 | PHENYL- AND PYRIDYLPIPEREIDINYE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM | Arena Pharmaceuticals, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| WO-2004076413-A2 | PHENYL- AND PYRIDYLPIPERIDINE-DERIVATIVES AS MODULATORS OF GLUCOSE METABOLISM | ARENA PHARMACEUTICALS, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-1431280-A1 | ARYL SULFAMATE DERIVATIVES | Kyowa Hakko Kogyo Co., Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-6140310-A | ADMINISTERING AN EFFECTIVE AMOUNT OF PHOSPHORUS PRODRUG IN A MAMMAL FOR TREATING A VIRAL INFECTION | DRUG INNOVATION & DESIGN, INC. (US) | 2000-10-31 | — | — | US | disclosed |
| US-5789608-A | LIPID SOLUBLE; DIFFUSE INTO CELLS AND TISSUE; VIRICIDES, ANTICANCER AGENTS | DRUG INNOVATION AND DESIGN, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| WO-1997040056-A1 | PRODRUGS OF ACYCLOVIR | DRUG INNOVATION & DESIGN, INC. (US) | 1997-10-30 | — | — | WO | disclosed |
| US-5627165-A | ANTIVIRAL AND ANTILEUKEMIA AGENTS | DRUG INNOVATION & DESIGN, INC. (US) | 1997-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | SULT1A1, STS, CYP26A1 | CA12 1120/4885CA1 147/4885CA2 465/4885 |
| US-20190314346-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | CA12 4029/4885CA1 3863/4885CA2 1311/4885 |
| US-20070066590-A1 | Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism | GPR119, PC, PLPBP | CA12 4872/4885CA1 4875/4885CA2 4069/4885 |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | CA12 4029/4885CA1 3863/4885CA2 1311/4885 |
| US-10953012-B2 | Heterocyclic compounds for the inhibition of pask | PASK, PDXK, PANK2 | CA12 4760/4885CA1 4318/4885CA2 3112/4885 |
| US-10966967-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | CA12 4029/4885CA1 3863/4885CA2 1311/4885 |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | CA12 4029/4885CA1 3863/4885CA2 1311/4885 |
| US-20200281905-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | CA12 4029/4885CA1 3863/4885CA2 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.